SP-16 is under clinical development by Serpin Pharma and currently in Phase II for Acute Lung Injury. According to GlobalData, Phase II drugs for Acute Lung Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SP-16 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SP-16 overview
SP-16 is under development for the treatment of type 1 diabetes, chemotherapy-induced peripheral neuropathy (CIPN), pneumonia due to SARS-CoV-2 infection and its associated ARDS, type 2 diabetes, myocardial infarction, eosinophilic esophagitis (EoE), chronic inflammatory, demyelinating neuropathy (CIDN), pemphigus vulgaris, acute kidney injury, acute lung injury, atopic dermatitis, alopecia areata and herpes zoster (shingles). The drug candidate is a serpin short peptide, derived from human alpha-1-antitrypsin. The drug candidate is administered through subcutaneous route. It acts by targeting low density lipoprotein receptor related protein 1.
Serpin Pharma overview
Serpin Pharma is a biotech company that provides targeted therapeutics for the treatment of inflammatory diseases. The company’s therapeutic products enhance the body’s natural immune response, reduce inflammation and help to restore the body’s immunity. It offers products in various therapeutic areas to treat acute myocardial infarction (AMI), acute lung injury, acute kidney injury, atopic dermatitis and chronic inflammatory demyelinating polyneuropathy (CIDP), among others. The company collaborates with diversified fields of research companies to develop therapeutics for unmet medical needs. It markets its products through distributors, retailers and third parties. Serpin Pharma is headquartered in Manassas, Virginia, the US.
For a complete picture of SP-16’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
